{
    "root": "b6245e25-3e64-40a8-a05e-d3b3e53cb787",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Quetiapine",
    "value": "20250306",
    "ingredients": [
        {
            "name": "QUETIAPINE FUMARATE",
            "code": "2S3PL1B6UJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8708"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "HYPROMELLOSE 2208 (100 MPA.S)",
            "code": "B1QE5P712K",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "HYPROMELLOSE 2208 (4000 MPA.S)",
            "code": "39J80LT57T",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SODIUM CITRATE",
            "code": "1Q73Q2JULR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53258"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        }
    ],
    "indications": {
        "text": "quetiapine atypical antipsychotic indicated treatment : schizophrenia . ( 1.1 ) bipolar disorder , manic , mixed episodes . ( 1.2 ) bipolar disorder , depressive episodes . ( 1.2 ) major depressive disorder , adjunctive therapy antidepressants . ( 1.3 )",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            },
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "swallow tablets whole split , chew crush . ( 2.1 ) take without food light meal ( approx . 300 calories ) . ( 2.1 ) administer daily , preferably evening . ( 2.1 ) geriatric : consider lower starting dose ( 50 mg/day ) , slower titration , careful monitoring initial dosing period elderly . ( 2.3 , 8.5 ) hepatic impairment : lower starting dose ( 50 mg/day ) slower titration may needed . ( 2.4 , 8.7 , 12.3 ) indication initial dose recommended dose maximum dose schizophrenia - adults ( 2.2 ) 300 mg/day 400 mg/day 800 mg/day 800 mg/day schizophrenia - adolescents ( 13 17 years ) ( 2.2 ) 50 mg/day 400 mg/day 800 mg/day 800 mg/day bipolar disorder manic mixed - acute monotherapy adjunct lithium divalproex -adults ( 2.2 ) 300 mg/day 400 mg/day 800 mg/day 800 mg/day bipolar disorder , manic acute monotherapy -children adolescents ( 10 17 years ) ( 2.2 ) 50 mg/day 400 mg/day 600 mg/day 600 mg/day bipolar disorder , depressive episodes - adults ( 2.2 ) 50 mg/day 300 mg/day 300 mg/day major depressive disorder , adjunctive therapy antidepressants - adults ( 2.2 ) 50 mg/day 150 mg/day 300 mg/day 300 mg/day",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            },
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "quetiapine extended-release tablets usp , 400 mg supplied white off-white , film-coated , modified capsule shaped tablets debossed \u2018 an431 \u2019 one side plain side . available follows : bottles 60 : ndc 65162-431-06 store quetiapine extended-release tablets 20\u00b0 25\u00bac ( 68\u00b0 77\u00baf ) ; excursions permitted 15\u00b0 30\u00bac ( 59\u00b0 86\u00baf ) [ usp controlled room temperature ] .",
    "adverseReactions": "hypersensitivity quetiapine excipients quetiapine extended-release tablets formulation . anaphylactic reported patients treated quetiapine extended-release tablets .",
    "indications_original": "Quetiapine is an atypical antipsychotic indicated for the treatment of: Schizophrenia. ( 1.1 ) Bipolar I disorder, manic, or mixed episodes. ( 1.2 ) Bipolar disorder, depressive episodes. ( 1.2 ) Major depressive disorder, adjunctive therapy with antidepressants. ( 1.3 )",
    "contraindications_original": "Swallow tablets whole and do not split, chew or crush. ( 2.1 ) Take without food or with a light meal (approx. 300 calories). ( 2.1 ) Administer once daily, preferably in the evening. ( 2.1 ) Geriatric Use: Consider a lower starting dose (50 mg/day), slower titration, and careful monitoring during the initial dosing period in the elderly. ( 2.3 , 8.5 ) Hepatic Impairment: Lower starting dose (50 mg/day) and slower titration may be needed. ( 2.4 , 8.7 , 12.3 ) Indication Initial Dose Recommended Dose Maximum Dose Schizophrenia - Adults ( 2.2 ) 300 mg/day 400 mg/day to 800 mg/day 800 mg/day Schizophrenia - Adolescents (13 to 17 years) ( 2.2 ) 50 mg/day 400 mg/day to 800 mg/day 800 mg/day Bipolar I Disorder manic or mixed - Acute monotherapy or adjunct to lithium or divalproex -Adults ( 2.2) 300 mg/day 400 mg/day to 800 mg/day 800 mg/day Bipolar I Disorder, manic Acute monotherapy -Children and Adolescents (10 to 17 years) ( 2.2 ) 50 mg/day 400 mg/day to 600 mg/day 600 mg/day Bipolar Disorder, Depressive Episodes - Adults ( 2.2 ) 50 mg/day 300 mg/day 300 mg/day Major Depressive Disorder, Adjunctive Therapy with Antidepressants - Adults ( 2.2 ) 50 mg/day 150 mg/day to 300 mg/day 300 mg/day",
    "warningsAndPrecautions_original": "Quetiapine Extended-Release Tablets USP, 400 mg are supplied as white to off-white, film-coated, modified capsule shaped tablets debossed with \u2018AN431\u2019 on one side and plain on other side.\n                  They are available as follows:\n                  Bottles of 60: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65162-431-06\n                  Store quetiapine extended-release tablets at 20\u00b0 to 25\u00baC (68\u00b0 to 77\u00baF); excursions permitted between 15\u00b0 to 30\u00baC (59\u00b0 to 86\u00baF) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Hypersensitivity to quetiapine or to any excipients in the quetiapine extended-release tablets formulation. Anaphylactic reactions have been reported in patients treated with quetiapine extended-release tablets.",
    "drug": [
        {
            "name": "Quetiapine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8707"
        }
    ]
}